NCT00902304 - Valsartan Intensified Primary Care Reduction of Blood Pressure Study | Biotech Hunter

Enrollment

2,337

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Hypertension

Interventions

DRUG

Valsartan and hydrochlorothiazide (HCTZ) - monotherapy

Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally

DRUG

Valsartan and amlodipine

From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally

DRUG

Usual care

As directed by investigator

DRUG

Valsartan

Valsartan 160mg per day to 320mg per day orally

DRUG

Valsartan and hydrochlorothiazide (HCTZ) - combination arm

Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally

Trial Locations (3)

Novartis Pharmaceuticals, East Hanover

Professor Garry Jennings-Co Principal Investigator, Melbourne

Professor Simon Stewart-Principal Investigator, Melbourne